Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Merck and Company    MRK

MERCK AND COMPANY

(MRK)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Merck and : Gets CHMP Positive Opinion for V920 Ebola Zaire Virus Vaccine

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/18/2019 | 07:23am EST

By Colin Kellaher

Merck & Co. (MRK) on Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use recommended approval of the V920 investigational vaccine for the Ebola Zaire virus.

The Kenilworth, N.J., drug maker said V920, if approved by the European Commission, would be authorized under the brand name Ervebo and indicated for active immunization of individuals 18 years of age or older.

The European Commission generally follows the CHMP's recommendations.

The U.S. Food and Drug Administration last month accepted and granted priority review to Merck's biologics license application for V920.

Write to Colin Kellaher at colin.kellaher@wsj.com

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MERCK AND COMPANY
07:22aMERCK AND : Gets EC Approval For Keytruda Regimens in Head, Neck Cancer
DJ
06:46aMERCK AND : European Commission Approves Two New Regimens of Merck's KEYTRUDA® (..
BU
11/19MERCK AND : & Co. Raises Quarterly Dividend by 10.9% to 61 Cents
DJ
11/19MERCK : Announces First-Quarter 2020 Dividend
BU
11/19FDA Accepts Avastin Biosimilar BLA From Biogen, Samsung BioLogics Venture
DJ
11/18MERCK AND : Ontario and Quebec provide reimbursement for HIV therapies PIFELTRO®..
AQ
11/18MERCK AND : Bayer Drug Vericiguat Meets Primary Endpoint in Phase 3 Study
DJ
11/18MERCK : and Bayer's Investigational Drug Vericiguat Meets Primary Endpoint in Ph..
BU
11/18MERCK AND : - BRAVECTO PLUS for Cats Receives Approval from US Food and Drug Adm..
AQ
11/15MERCK AND : AstraZeneca - US FDA accepts regulatory submission for selumetinib i..
AQ
More news
Financials (USD)
Sales 2019 46 560 M
EBIT 2019 16 323 M
Net income 2019 10 062 M
Debt 2019 20 850 M
Yield 2019 2,62%
P/E ratio 2019 21,9x
P/E ratio 2020 17,0x
EV / Sales2019 5,08x
EV / Sales2020 4,74x
Capitalization 216 B
Chart MERCK AND COMPANY
Duration : Period :
Merck and Company Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MERCK AND COMPANY
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 18
Average target price 97,65  $
Last Close Price 84,65  $
Spread / Highest target 24,0%
Spread / Average Target 15,4%
Spread / Lowest Target 6,32%
EPS Revisions
Managers
NameTitle
Kenneth C. Frazier Chairman, President & Chief Executive Officer
Robert M. Davis CFO & Executive Vice President-Global Services
Sandy Tremps Vice President-R&D IT CIO
James H. Scholefield Chief Information & Digital Officer
Thomas Henry Glocer Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
MERCK AND COMPANY10.78%215 518
JOHNSON & JOHNSON4.48%354 829
ROCHE HOLDING AG24.03%260 464
PFIZER-13.72%208 415
NOVARTIS20.08%204 021
NOVO NORDISK AS29.07%134 235